Accueil>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> PI3K>>WYE-687 dihydrochloride

WYE-687 dihydrochloride

Catalog No.GC38473

Le dichlorhydrate de WYE-687 est un inhibiteur de mTOR compétitif pour l'ATP avec une IC50 de 7 nM. Le dichlorhydrate de WYE-687 inhibe simultanément l'activation de mTORC1 et mTORC2. WYE-687 inhibe également PI3Kα et PI3Kγ avec des IC50 de 81 nM et 3,11 μM, respectivement.

Products are for research use only. Not for human use. We do not sell to patients.

WYE-687 dihydrochloride Chemical Structure

Cas No.: 1702364-87-1

Taille Prix Stock Qté
1mg
245,00 $US
En stock
2mg
428,00 $US
En stock
5mg
734,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

WYE-687 dihydrochloride is an ATP-competitive mTOR inhibitor with an IC50 of 7 nM[1]. WYE-687 dihydrochloride concurrently inhibits activation of mTORC1 and mTORC2[2]. WYE-687 also inhibits PI3Kα and PI3Kγ with IC50s of 81 nM and 3.11 μM, respectively[1].

[1]. Yu K, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009 Aug 1;69(15):6232-40. [2]. Cheng F, et al. Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent. Biochem Biophys Res Commun. 2016 Feb 5;470(2):324-330.

Avis

Review for WYE-687 dihydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for WYE-687 dihydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.